Therefore, it appears that, as has been recently revealed in an extensive body of work for breast cancer [26, 27, 29, 30], additional cancer types such as HNSCC may require AKT isoform analysis to predict the outcome of pan-AKT inhibitors. This evidence concerns the gene AKT1 and head and neck squamous cell carcinoma.